Loading
Trevarx Biomedical
Trevarx Biomedical is a Philadelphia company attaching a radioactive atom to a PARP inhibitor so that radiation is released right at a tumour cell's DNA. Its first drug, AlphaPARP, is being prepared for ovarian cancer.
Also called: Trevarx Biomedical, Inc.Trevarx
Overview
Trevarx Biomedical, Inc. is building a DNA-directed alpha radiopharmaceutical platform. Its first therapeutic, AlphaPARP, is astatine-211 attached to a PARP inhibitor backbone (Parthanatine), designed to bind activated PARP1 at sites of tumour DNA damage so that alpha energy is deposited next to the DNA; the company says it is seeking a USD 35 million Series A. A 2026 National Cancer Institute SBIR award funds preparation for a phase 1 IND of the agent in ovarian cancer, and the award abstract describes a companion PET imaging agent that binds the same target for patient selection.
Headquarters
Philadelphia, PA, US
Scorecard
All companies#695of 1706 companies, score 4
- targets +2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 1R44CA310342-01A1: Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Startup
Website
Products
1PreclinicalTargeted alpha radiopharmaceutical (small molecule)
AlphaPARP is an experimental radioactive drug from Trevarx Biomedical that carries an alpha-emitting atom to the DNA-repair enzyme PARP1 in cancer cells. It is being prepared for a first trial in ovarian cancer.
Notes
- Company website and the NIH RePORTER record read on 4 November 2026. Founding year not stated on the website.
Connected
6Similar pages
- CompanyZ-Alpha Therapeutics
- TrialA Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
Shares PARP, Ovarian cancer.
- TrialA Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
Shares PARP, Ovarian cancer.
- TrialStudy of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Shares PARP, Ovarian cancer.
- TargetALC1 (CHD1L)
Shares PARP, Ovarian cancer.
- TrialAscending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Shares PARP, Ovarian cancer.
- Companypharma&
Shares PARP, Ovarian cancer.
- TreatmentDSB2455
Shares PARP, Ovarian cancer.
cancers
fronts
technologies
targets
drugs
PreclinicalTargeted alpha radiopharmaceutical (small molecule)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nih.gov · 1
trevarx.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/